GPCR – structure therapeutics inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

GPCR

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

9/23

08:53 am

gpcr

Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.

Medium Report

Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.

Report

9/23

08:34 am

gpcr

Rating for GPCR

Medium Report

Rating for GPCR

Report

9/23

08:06 am

gpcr

Rating for GPCR

Medium Report

Rating for GPCR

Report

9/23

08:06 am

gpcr

Rating for GPCR

Medium Report

Rating for GPCR

Report

9/23

07:59 am

gpcr

Structure Therapeutics Inc. (NASDAQ: GPCR) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $118.00 price target on the stock.

Medium Report

Structure Therapeutics Inc. (NASDAQ: GPCR) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $118.00 price target on the stock.

Report

9/23

07:59 am

gpcr

Structure Therapeutics Inc. (NASDAQ: GPCR) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $118.00 price target on the stock.

Medium Report

Structure Therapeutics Inc. (NASDAQ: GPCR) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $118.00 price target on the stock.

Report

9/16

12:11 pm

gpcr

Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.

Low Report

Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.

Report

9/16

11:48 am

gpcr

Rating for GPCR

Low Report

Rating for GPCR

Report

9/9

12:14 pm

gpcr

Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.

Low Report

Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.

Report

9/9

11:40 am

gpcr

Rating for GPCR

Medium Report

Rating for GPCR

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.